Catalent, Inc. (NYSE:CTLT) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Catalent, Inc. (NYSE:CTLT) have been assigned a consensus recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $63.40.

A number of equities analysts have weighed in on CTLT shares. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a report on Friday, November 22nd. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd.

Insider Transactions at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by company insiders.

Institutional Trading of Catalent

A number of hedge funds have recently made changes to their positions in the stock. Brooklyn Investment Group purchased a new stake in Catalent during the third quarter valued at about $31,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalent during the 2nd quarter valued at about $42,000. Sentry Investment Management LLC bought a new stake in Catalent in the 3rd quarter worth approximately $53,000. Longfellow Investment Management Co. LLC boosted its stake in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares during the last quarter.

Catalent Stock Performance

Shares of Catalent stock opened at $61.11 on Monday. The firm has a market capitalization of $11.09 billion, a P/E ratio of -27.04, a price-to-earnings-growth ratio of 2.43 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The business’s fifty day simple moving average is $59.90 and its 200 day simple moving average is $58.51. Catalent has a 12 month low of $36.74 and a 12 month high of $61.50.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the firm earned ($0.10) earnings per share. The firm’s revenue was up 4.2% compared to the same quarter last year. As a group, analysts anticipate that Catalent will post 0.84 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.